Intrinsic Value Partners LLC Sells 15,137 Shares of Moderna, Inc. (NASDAQ:MRNA)

Intrinsic Value Partners LLC reduced its holdings in shares of Moderna, Inc. (NASDAQ:MRNA) by 29.5% in the fourth quarter, Holdings Channel.com reports. The fund owned 36,255 shares of the company’s stock after selling 15,137 shares during the quarter. Moderna comprises about 1.5% of Intrinsic Value Partners LLC’s portfolio, making the stock its 18th largest holding. Intrinsic Value Partners LLC’s holdings in Moderna were worth $1,507,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Wilmington Savings Fund Society FSB raised its position in Moderna by 295.0% during the 4th quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company’s stock valued at $33,000 after purchasing an additional 587 shares in the last quarter. MassMutual Private Wealth & Trust FSB raised its position in Moderna by 58.2% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 1,057 shares of the company’s stock valued at $44,000 after purchasing an additional 389 shares in the last quarter. Blue Trust Inc. increased its holdings in shares of Moderna by 53.1% in the 4th quarter. Blue Trust Inc. now owns 1,119 shares of the company’s stock valued at $47,000 after acquiring an additional 388 shares during the period. EMC Capital Management increased its holdings in shares of Moderna by 311.2% in the 4th quarter. EMC Capital Management now owns 1,250 shares of the company’s stock valued at $52,000 after acquiring an additional 946 shares during the period. Finally, Larson Financial Group LLC increased its holdings in shares of Moderna by 53.5% in the 3rd quarter. Larson Financial Group LLC now owns 910 shares of the company’s stock valued at $61,000 after acquiring an additional 317 shares during the period. 75.33% of the stock is owned by institutional investors.

Analysts Set New Price Targets

MRNA has been the topic of a number of analyst reports. Barclays cut their price target on Moderna from $125.00 to $111.00 and set an “overweight” rating on the stock in a report on Friday, November 8th. Leerink Partners cut their price target on Moderna from $31.00 to $27.00 and set an “underweight” rating on the stock in a report on Thursday, January 16th. Wolfe Research assumed coverage on Moderna in a report on Friday, November 15th. They issued an “underperform” rating and a $40.00 price target on the stock. HSBC upgraded Moderna from a “hold” rating to a “buy” rating and set a $58.00 target price on the stock in a research note on Monday, November 18th. Finally, Bank of America dropped their target price on Moderna from $41.00 to $34.00 and set an “underperform” rating on the stock in a research note on Tuesday. Four analysts have rated the stock with a sell rating, fourteen have assigned a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Moderna presently has a consensus rating of “Hold” and an average price target of $66.89.

Insider Activity

In related news, insider Shannon Thyme Klinger sold 1,418 shares of the company’s stock in a transaction dated Friday, November 29th. The stock was sold at an average price of $42.79, for a total value of $60,676.22. Following the completion of the transaction, the insider now owns 19,717 shares of the company’s stock, valued at approximately $843,690.43. This represents a 6.71 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders sold a total of 2,664 shares of company stock valued at $115,210 in the last quarter. 15.70% of the stock is currently owned by company insiders.

Moderna Trading Up 3.4 %

Shares of MRNA stock opened at $32.99 on Friday. The business has a 50-day simple moving average of $39.09 and a 200-day simple moving average of $55.77. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.39 and a quick ratio of 4.20. Moderna, Inc. has a 52-week low of $29.25 and a 52-week high of $170.47.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.